T Breidert

Summary

Country: France

Publications

  1. ncbi Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease
    T Breidert
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Pitie Salpetriere, Paris, France
    J Neurochem 82:615-24. 2002
  2. ncbi The role of glial reaction and inflammation in Parkinson's disease
    E C Hirsch
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, 75651 Paris Cedex 13, France
    Ann N Y Acad Sci 991:214-28. 2003

Detail Information

Publications2

  1. ncbi Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease
    T Breidert
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Pitie Salpetriere, Paris, France
    J Neurochem 82:615-24. 2002
    ..Since pioglitazone affects primarily the SNpc in our model, different PPARgamma-independent mechanisms may regulate glial activation in the dopaminergic terminals compared with the dopaminergic cell bodies after acute MPTP intoxication...
  2. ncbi The role of glial reaction and inflammation in Parkinson's disease
    E C Hirsch
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, 75651 Paris Cedex 13, France
    Ann N Y Acad Sci 991:214-28. 2003
    ..Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease...